Northwest Biotherapeutics Stock Current Valuation
| NWBO Stock | USD 0.27 0.01 3.85% |
Valuation analysis of Northwest Biotherapeutics helps investors to measure Northwest Biotherapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Northwest Biotherapeutics' price fluctuation is out of control at this time. Calculation of the real value of Northwest Biotherapeutics is based on 3 months time horizon. Increasing Northwest Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Northwest otc stock is determined by what a typical buyer is willing to pay for full or partial control of Northwest Biotherapeutics. Since Northwest Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Northwest OTC Stock. However, Northwest Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.27 | Real 0.24 | Hype 0.27 |
The intrinsic value of Northwest Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Northwest Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Northwest Biotherapeutics helps investors to forecast how Northwest otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Northwest Biotherapeutics more accurately as focusing exclusively on Northwest Biotherapeutics' fundamentals will not take into account other important factors: Northwest Biotherapeutics OTC Stock Current Valuation Analysis
Northwest Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Northwest Biotherapeutics Current Valuation | 1.03 B |
Most of Northwest Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Northwest Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Northwest Biotherapeutics has a Current Valuation of 1.03 B. This is 92.86% lower than that of the Biotechnology sector and 77.92% lower than that of the Health Care industry. The current valuation for all United States stocks is 93.83% higher than that of the company.
Northwest Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Northwest Biotherapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Northwest Biotherapeutics could also be used in its relative valuation, which is a method of valuing Northwest Biotherapeutics by comparing valuation metrics of similar companies.Northwest Biotherapeutics is currently under evaluation in current valuation category among its peers.
Northwest Fundamentals
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Shares Owned By Insiders | 10.04 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 14.14 M | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X | ||||
| Revenue | 1 M | ||||
| Gross Profit | 1 M | ||||
| EBITDA | 184.72 M | ||||
| Net Income | 179.13 M | ||||
| Cash And Equivalents | 9.43 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 25.16 M | ||||
| Debt To Equity | (16.14) % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (38.3 M) | ||||
| Short Ratio | 13.54 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | -0.0115 | ||||
| Market Capitalization | 705.3 M | ||||
| Total Asset | 40.16 M | ||||
| Retained Earnings | (862.01 M) | ||||
| Working Capital | (40.83 M) | ||||
| Current Asset | 24.1 M | ||||
| Current Liabilities | 64.93 M | ||||
| Z Score | -0.6 | ||||
| Net Asset | 40.16 M |
About Northwest Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Northwest Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Northwest Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Northwest Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Northwest Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Northwest Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Northwest Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Northwest OTC Stock
| 0.48 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.36 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.36 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.34 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.31 | EVLO | Evelo Biosciences | PairCorr |
The ability to find closely correlated positions to Northwest Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Northwest Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Northwest Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Northwest Biotherapeutics to buy it.
The correlation of Northwest Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Northwest Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Northwest Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Northwest Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.